Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!


Lawmakers approve expanding access to cannabis for research purposes

After decades of keeping researchers largely in the dark when it comes to cannabis, the federal government is ready to shine a little light for the scientific community.

The Medical Marijuana and Cannabidiol Research Expansion Act passed in the U.S. House in July and was approved in the Senate by a voice vote on Nov. 16. President Biden intends to sign it into law, according to Bloomberg News. The bill will expand opportunities for cannabis research and remove a lot of red tape surrounding the issue.

Related: Indiana Lawmakers Consider Cannabis Legalization

Top 5 CBD Oil Brands for 2022

The news comes just weeks after Biden announced a handful of federal cannabis reforms, including initiating a review of cannabis’ status as a Schedule I drug under the Controlled Substances Act. Schedule I drugs are considered to have a high potential for abuse and no accepted medical uses. Medical marijuana, in one form or another, is legal in 46 states, calling into question whether cannabis should be scheduled so harshly.

For decades, research into cannabis has been hampered by its status as a Schedule I drug. Until just last year, the only cannabis that could be grown legally for research purposes came from the University of Mississippi. Researchers were hamstrung not only by the lack of cannabis available, but also because it was low-quality and did not match the level of cannabis being produced for the nation’s legal and illicit markets. The Drug Enforcement Administration has since granted approval to six additional producers of cannabis for research.

A provision of the bill heading to Biden’s desk directly addresses the shortage of cannabis for research by directing the DEA to “assess whether there is an adequate and uninterrupted supply of marijuana for research purposes.”

Related: Massachusetts Cannabis Reform Signed Into Law

Top 5 CBD Oil Brands for 2022

One key way this bill will further expand the amount of cannabis available for research is by allowing the DEA to approve certain licensed institutions — medical schools, research institutions and practitioners, for example — to produce and distribute their own cannabis for research purposes. The bill also allows commercial producers of cannabis-derived drugs to register with the DEA in a more streamlined process.

Additional provisions in the bill will allow physicians to freely discuss potential benefits of medical marijuana or cannabinoid use with patients, a practice that is currently prohibited under federal law. The bill will also require that relevant federal agencies, such as the National Institutes of Health, produce reports on the therapeutic benefits of cannabis for various conditions, such as epilepsy

Lawmakers approve expanding access to cannabis for research purposes


About Cannin: Your Cannabis Stocks Resource

78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.

Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021. 

Use Cannin as your resource for:

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.

Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +34% Gains in 2022
  • +56% Gains in 2021
  • +30% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at cannin.com.